Stock FULC FULCRUM THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Fulcrum Therapeutics, Inc.

Equities

FULC

US3596161097

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
7.14 USD +0.14% Intraday chart for Fulcrum Therapeutics, Inc. +4.39% +5.78%
03-18 Fulcrum Therapeutics Appoints Patrick Horn as Chief Medical Officer MT
03-18 Fulcrum Therapeutics, Inc. Announces Executive Changes CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
GL
Fulcrum Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Fulcrum Therapeutics Appoints Patrick Horn as Chief Medical Officer
MT
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
GL
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
AQ
Fulcrum Therapeutics, Inc. Announces Executive Changes
CI
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to S&P Pharmaceuticals Select Industry Index
CI
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
GL
GSK: Dr Jeannie Lee joins the Board of Directors
CF
Piper Sandler Adjusts Price Target on Fulcrum Therapeutics to $15 From $13, Maintains Overweight Rating
MT
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
AQ
Transcript : Fulcrum Therapeutics, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
GL
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
AQ
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FULC Stock
  4. News Fulcrum Therapeutics, Inc.